A new scoping review protocol has been introduced to explore the application of polygenic risk scores (PRS) in common neurodegenerative diseases. This initiative aims to map the current landscape and identify gaps in the translational research of PRS, encompassing diseases like Multiple Sclerosis, Parkinson’s, Alzheimer’s, and Amyotrophic Lateral Sclerosis.
Study Objective and Scope
The primary goal of this protocol is to meticulously outline the methodology for conducting a scoping review on PRS within the realm of neurodegenerative diseases. The review intends to assess how PRS are utilized across various stages of translational research, from early development phases to their implementation in clinical settings. Key areas of focus include risk prediction, early diagnosis, prognosis, and informed treatment decision-making.
Methodology and Inclusion Criteria
The review will systematically include both peer-reviewed articles and grey literature published in English or German. Researchers will concentrate on studies that apply PRS to the specified neurodegenerative conditions at any translational research phase. To ensure comprehensive coverage, the search strategy will be developed based on the population, context, and concept framework, with two independent reviewers conducting the information search.
• Comprehensive mapping of PRS applications in neurodegenerative research
• Identification of translational research stages utilizing PRS
• Evaluation of PRS effectiveness in risk prediction and clinical decision-making
The findings will be descriptively presented, aligning with the predefined research questions to highlight the current state of PRS integration in neurodegenerative disease research.
Insights from this scoping review will provide valuable information for clinicians and researchers aiming to leverage PRS in improving diagnostic and prognostic strategies. By identifying existing applications and gaps, the study will facilitate the advancement of personalized medicine approaches in managing neurodegenerative diseases.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
